President Trump has announced federal deals to cut prices on leading obesity, diabetes, and migraine drugs, and the plan promises lower monthly costs for patients while claiming big savings for taxpayers.

Public health data show obesity affects a large slice of the adult population, with the Centers for Disease Control and Prevention reporting just over 40% of American adults qualify as obese. That scale makes drug pricing a national issue, and the new announcements aim to bring prices down where many have been out of reach.

The White House issued a fact sheet announcing Most Favored Nation pricing arrangements with major drugmakers Eli Lilly & Company and Novo Nordisk, and the effort was presented as a targeted move to lower costs on popular obesity medicines. The administration framed the deals as both a consumer and taxpayer win, stressing that discounted prices will be available quickly.

The agreements single out popular GLP-1 therapies. Wegovy and Ozempic, both produced by Novo Nordisk, are set to fall to $350 per month from prior levels that reached $1,350 and $1,000 per month respectively, a dramatic drop that could significantly broaden access for many patients.

Eli Lilly’s offerings are on the list too, with Zepbound and Orforglipron expected to decline from roughly $1,068 a month to about $346. Those cuts are designed to make these next-generation medications competitive with older, cheaper options and to blunt sticker shock for people who need ongoing treatment.

The administration plans to push online purchasing through a dedicated portal called TrumpRx, which is scheduled to be operational by January and should let people buy at the negotiated prices without complex insurance hurdles. “In the event that the FDA later approves the Wegovy pill, or certain similar ‘GLP-1’ drugs in each company’s pipeline intended to be taken orally rather than as a shot, the initial dose of those drugs will be priced at $150 per month through TrumpRx,” the fact sheet stressed.

The release argues these negotiated rates change the budget math for federal health programs. “[t]he historic reduction in prices negotiated by President Trump will enable Medicare and Medicaid to cover obesity drugs for adults at a dramatically lower cost to taxpayers than that proposed by the Biden Administration.” That claim is central to the administration’s pitch that lower unit prices lead to overall fiscal benefits.

The document also specifies how the reduced pricing will apply within Medicare, stating plainly that “The Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245” while “Medicare beneficiaries will pay a co-pay of just $50 per month.” Those figures aim to make chronic treatment predictable and affordable for seniors on fixed incomes.

The agreements extend beyond weight-loss drugs to treatments for diabetes and migraine sufferers, offering relief for other costly therapies. Eli Lilly will offer its migraine medication Emgality at $299 per pen and diabetes drug Trulicity at $389 per month, both positioned as more affordable options than they have been at retail pricing.

Insulin affordability is also part of the package, with the announcement noting that manufacturers will cap common insulin products at a low monthly cost. Novo Nordisk committed that it “will provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month of supply,” a step the administration says will protect patients who rely on insulin daily.